Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current Deferred Tax LiabilityNon-Current Deferred Tax LiabilityOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Oric Pharmaceuticals (ORIC) Preferred Stock Liabilities (2019 - 2020)

Oric Pharmaceuticals filings provide 2 years of Preferred Stock Liabilities readings, the most recent being $15.4 million for Q1 2020.

  • Quarterly Preferred Stock Liabilities fell 70.98% to $15.4 million in Q1 2020 from the year-ago period, while the trailing twelve-month figure was $15.4 million through Mar 2020, down 70.98% year-over-year, with the annual reading at $178.1 million for FY2019, 66.0% up from the prior year.
  • Preferred Stock Liabilities hit $15.4 million in Q1 2020 for Oric Pharmaceuticals, down from $178.1 million in the prior quarter.
  • Across five years, Preferred Stock Liabilities topped out at $178.1 million in Q4 2019 and bottomed at $15.4 million in Q3 2019.